Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1982 Jan;21(1):62–65. doi: 10.1128/aac.21.1.62

Activities of tobramycin and azlocillin alone and in combination against experimental osteomyelitis caused by Pseudomonas aeruginosa.

C W Norden, M A Shaffer
PMCID: PMC181830  PMID: 6805423

Abstract

Azlocillin and tobramycin were used alone and in combination in the treatment of chronic osteomyelitis due to Pseudomonas aeruginosa in rabbits. This combination showed in vitro synergy measured by both the checkerboard technique and time-kill curves. A marked inoculum effect was demonstrated in vitro with azlocillin and the infecting strain of P. aeruginosa. The minimal inhibitory concentration of azlocillin, with an inoculum of 10(5) organisms, was 12.5 micrograms/ml; when the inoculum size was increased to 10(7) organisms, the minimal inhibitory concentration rose to more than 500 micrograms/ml. In therapeutic trials, the combination of azlocillin and tobramycin, given for 28 days, was significantly better than either no therapy or azlocillin alone, but was not significantly better than tobramycin alone. Even after 4 weeks of combined therapy with azlocillin and tobramycin, P. aeruginosa was recovered from the bones of 60% of the treated rabbits.

Full text

PDF
63

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Coppens L., Klastersky J. Comparative study of anti-pseudomonas activity of azlocillin, mezlocillin, and ticarcillin. Antimicrob Agents Chemother. 1979 Mar;15(3):396–399. doi: 10.1128/aac.15.3.396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Fu K. P., Neu H. C. Azlocillin and mezlocillin: new ureido penicillins. Antimicrob Agents Chemother. 1978 Jun;13(6):930–938. doi: 10.1128/aac.13.6.930. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Norden C. W. Experimental osteomyelitis. I. A description of the model. J Infect Dis. 1970 Nov;122(5):410–418. doi: 10.1093/infdis/122.5.410. [DOI] [PubMed] [Google Scholar]
  4. Norden C. W. Experimental osteomyelitis. IV. Therapeutic trials with rifampin alone and in combination with gentamicin, sisomicin, and cephalothin. J Infect Dis. 1975 Nov;132(5):493–499. doi: 10.1093/infdis/132.5.493. [DOI] [PubMed] [Google Scholar]
  5. Norden C. W., Keleti E. Experimental osteomyelitis caused by Pseudomonas aeruginosa. J Infect Dis. 1980 Jan;141(1):71–75. doi: 10.1093/infdis/141.1.71. [DOI] [PubMed] [Google Scholar]
  6. Norden C. W., Myerowitz R. L., Keleti E. Experimental osteomyelitis due to Staphylococcus aureus or Pseudomonas aeruginosa: a radiographic-pathological correlative analysis. Br J Exp Pathol. 1980 Aug;61(4):451–460. [PMC free article] [PubMed] [Google Scholar]
  7. Stewart D., Bodey G. P. Azlocillin: in vitro studies of a new semisynthetic penicillin. Antimicrob Agents Chemother. 1977 May;11(5):865–870. doi: 10.1128/aac.11.5.865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. White A. R., Comber K. R., Sutherland R. Comparative bactericidal effects of azlocillin and ticarcillin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1980 Jul;18(1):182–189. doi: 10.1128/aac.18.1.182. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES